Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
GLP-1 receptor agonists in adolescent obesity: Incretin-based therapies during a sensitive developmental period
Mills AM, Noble EE
Appetite, 2026;:108729
GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape
Ahmed MM, Nazari R, Othman ZK, et al.
Therapeutic advances in endocrinology and metabolism, 2026;17:20420188261472587
A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors
Iqbal S, Javed F, Oyibo SO
Cureus, 2026;18(7):e113391
Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE)
Rodbard HW, Irace C, Lobo J, et al.
Diabetes, obesity & metabolism, 2026
A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States
McGovern AJ, Cinfio F, Luo R
PharmacoEconomics, 2026
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1
Busetto L, Contreras CO, Christensen MH, et al.
Diabetes, obesity & metabolism, 2026
Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment
Khan S, Jamal A, Qadri M, et al.
Medicine;105(30):e49916
Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis
Quan AT, Nguyen HL, Nguyen TMT
Diabetes & metabolic syndrome, 2026;20(7):103466
Effects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis
Sobral MVS, Menechini RB, Marçal JBC, et al.
Schizophrenia research, 2026;297:8-16
Tirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report
Rantanen R, Olson C, Raval C
Journal of clinical psychopharmacology, 2026
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study
Wei Y, Gong Y, Gong J, et al.
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2026;46(1):2701996
Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis
Kamrul-Hasan ABM, Khalil I, Dutta D, et al.
Endocrinology, diabetes & metabolism;9(4):e70291
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation
Azzam AY, Essibayi MA, Rai P, et al.
JACC. Advances;5(7):102917
Advances in proteomics research related to semaglutide: evidence from humans and animals
Jia Q, Mu H, Wang Y, et al.
Journal of endocrinological investigation, 2026
Impact of semaglutide on cognitive function in patients with type 2 diabetes and mild cognitive impairment: a 24-month observational study
Cassataro G, Scriffignano S, Geraci G, et al.
Internal and emergency medicine, 2026
Retatrutide and the urinary tract infection signal: Is the answer hidden in timing?
Koufakis T, Argyrakopoulou G, Kokkinos A, et al.
European journal of internal medicine, 2026;:107099
Semaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial
Vanlaer Y, Embo N, Bochanen N, et al.
BMJ open, 2026;16(7):e118191
One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy
Gao SX, Borner T
Appetite, 2026;:108723
Can semaglutide influence tumor biomarkers? Insight from a clinical case
Schianchi A, Mauri F, Polli C
Journal of food and drug analysis;34(2):172-175
When Side Effects Become Therapies: A Mechanistic Taxonomy of Adverse Drug Reactions as Translational Signals for Drug Repositioning
Emanuele E, Minoretti P, Ballerio M, et al.
Fundamental & clinical pharmacology;40(4):e70109